Table 1:

Clinical characteristics of the cohort (N=79)

Variables	N=79
Age at Diagnosis, Median (Mean), range	57 (55.9), 24–72
Histology
High-grade serous	68 (86%)
Other*	11 (14%)
Stage at diagnosis
I/II	3 (4%)
III	45 (57%)
IV	31 (39%)
BRCA 1/2 Mutations (germline or somatic)
Wildtype	52 (66%)
BRCA-mutated	21 (27%)
Not tested	6 (7%)
Optimal debulking (25 missing)
No	10 (18%)
Yes	44 (82%)
Primary chemo treatment (12 missing)
Neoadjuvant	26 (39%)
Adjuvant	41 (61%)
Platinum status at ICI initiation
Sensitive	13 (16%)
Resistant/Refractory	66 (84%)
ICI target
PD-1/PD-L1	35 (44%)
PD-1/PD-L1+CTLA-4	27 (34%)
PD-1/PD-L1+Other	12 (16%)
Other	5 (6%)
CA-125, Median(Mean), range	158 (618.5), 9–7087
BMI, Median(Mean), range	25.9 (27.2), 18.5–50.2
ICI duration in months, Median (Mean), range	2.8 (3.9), 0.6–13.8
Long ICI (ICI duration ≥24 weeks)	16 (20%)
Short ICI (ICI duration <24 weeks)	63 (80%)
Months lag from Dx to ICI, Median(Mean), range	39.7 (45.9), 10.1–205.9
Treatment Lines
Pre-ICI (8 missing), Median (Mean), range	4 (4.1), 1–12
Post-ICI Median (Mean), range	2 (2.9), 1–8
Total (8 missing), Median(Mean), range	7 (8.1), 4–16

ICI, immune checkpoint inhibitor; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; CTLA-4, cytotoxic T-Lymphocyte associated protein 4; dx, diagnosis

^*Other histologies: clear cell carcinoma (n=5), endometrioid carcinoma (n=2), low grade serous (n=2), mixed serous and endometrioid (n=1), or adenocarcinoma not otherwise specified (NOS) (n=1)